GB0715937D0 - Method of treatment og duchenne muscular dystrophy - Google Patents

Method of treatment og duchenne muscular dystrophy

Info

Publication number
GB0715937D0
GB0715937D0 GBGB0715937.9A GB0715937A GB0715937D0 GB 0715937 D0 GB0715937 D0 GB 0715937D0 GB 0715937 A GB0715937 A GB 0715937A GB 0715937 D0 GB0715937 D0 GB 0715937D0
Authority
GB
United Kingdom
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
duchenne
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0715937.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Vastox PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vastox PLC filed Critical Vastox PLC
Priority to GBGB0715937.9A priority Critical patent/GB0715937D0/en
Publication of GB0715937D0 publication Critical patent/GB0715937D0/en
Priority to MX2009011967A priority patent/MX2009011967A/es
Priority to EP08785566A priority patent/EP2188270A2/en
Priority to ARP080103560A priority patent/AR068810A1/es
Priority to US12/192,053 priority patent/US20090048314A1/en
Priority to KR1020097023605A priority patent/KR20100075777A/ko
Priority to TW097131010A priority patent/TW200911767A/zh
Priority to PE2008001385A priority patent/PE20090604A1/es
Priority to JP2010520499A priority patent/JP2010535830A/ja
Priority to PCT/EP2008/006718 priority patent/WO2009021748A2/en
Priority to CL2008002391A priority patent/CL2008002391A1/es
Priority to CA002685590A priority patent/CA2685590A1/en
Priority to BRPI0811548-6A2A priority patent/BRPI0811548A2/pt
Priority to EP08785565A priority patent/EP2176246A2/en
Priority to CN200880015864A priority patent/CN101679323A/zh
Priority to MX2009011916A priority patent/MX2009011916A/es
Priority to AU2008286324A priority patent/AU2008286324A1/en
Priority to AU2008286325A priority patent/AU2008286325A1/en
Priority to CA002685939A priority patent/CA2685939A1/en
Priority to PCT/EP2008/006719 priority patent/WO2009021749A2/en
Priority to BRPI0811315-7A2A priority patent/BRPI0811315A2/pt
Priority to JP2010520498A priority patent/JP2010535829A/ja
Priority to RU2009141831/04A priority patent/RU2009141831A/ru
Priority to CN2008800158003A priority patent/CN101896475A/zh
Priority to US12/599,970 priority patent/US8138351B2/en
Priority to IL201908A priority patent/IL201908A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GBGB0715937.9A 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy Ceased GB0715937D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy
US12/599,970 US8138351B2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
BRPI0811548-6A2A BRPI0811548A2 (pt) 2007-08-15 2008-08-14 Forma polimórfica de um composto, composição farmacêutica, e, processo para sintetizar uma forma polimórfica de um composto
CN200880015864A CN101679323A (zh) 2007-08-15 2008-08-14 用于治疗杜兴氏肌营养不良症的化合物的多晶型体
ARP080103560A AR068810A1 (es) 2007-08-15 2008-08-14 Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden
US12/192,053 US20090048314A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
KR1020097023605A KR20100075777A (ko) 2007-08-15 2008-08-14 뒤시엔느 근이영양증의 치료를 위한 화합물의 다형체
TW097131010A TW200911767A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
PE2008001385A PE20090604A1 (es) 2007-08-15 2008-08-14 Tratamiento de distrofia muscular de duchenne
JP2010520499A JP2010535830A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用化合物の製造
PCT/EP2008/006718 WO2009021748A2 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of duchenne muscular dystrophy
CL2008002391A CL2008002391A1 (es) 2007-08-15 2008-08-14 Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne.
CA002685590A CA2685590A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
MX2009011967A MX2009011967A (es) 2007-08-15 2008-08-14 Formas polimorficas de un compuesto para el tratamiento de la distrofia muscular de duchenne.
EP08785565A EP2176246A2 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of duchenne muscular dystrophy
EP08785566A EP2188270A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy
MX2009011916A MX2009011916A (es) 2007-08-15 2008-08-14 Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.
AU2008286324A AU2008286324A1 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of Duchenne muscular dystrophy
AU2008286325A AU2008286325A1 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of Duchenne muscular dystrophy
CA002685939A CA2685939A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
PCT/EP2008/006719 WO2009021749A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy
BRPI0811315-7A2A BRPI0811315A2 (pt) 2007-08-15 2008-08-14 Processo para a preparação de um composto
JP2010520498A JP2010535829A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体
RU2009141831/04A RU2009141831A (ru) 2007-08-15 2008-08-14 Лечение мышечной дистрофии дюшенна
CN2008800158003A CN101896475A (zh) 2007-08-15 2008-08-14 用于治疗杜兴氏肌营养不良的化合物的制备
IL201908A IL201908A0 (en) 2007-08-15 2009-11-03 Polymorphs of a compound for the treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0715937D0 true GB0715937D0 (en) 2007-09-26

Family

ID=38566447

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0715937.9A Ceased GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Country Status (17)

Country Link
US (2) US20090048314A1 (cg-RX-API-DMAC7.html)
EP (2) EP2188270A2 (cg-RX-API-DMAC7.html)
JP (2) JP2010535830A (cg-RX-API-DMAC7.html)
KR (1) KR20100075777A (cg-RX-API-DMAC7.html)
CN (2) CN101896475A (cg-RX-API-DMAC7.html)
AR (1) AR068810A1 (cg-RX-API-DMAC7.html)
AU (2) AU2008286325A1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811315A2 (cg-RX-API-DMAC7.html)
CA (2) CA2685590A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002391A1 (cg-RX-API-DMAC7.html)
GB (1) GB0715937D0 (cg-RX-API-DMAC7.html)
IL (1) IL201908A0 (cg-RX-API-DMAC7.html)
MX (2) MX2009011967A (cg-RX-API-DMAC7.html)
PE (1) PE20090604A1 (cg-RX-API-DMAC7.html)
RU (1) RU2009141831A (cg-RX-API-DMAC7.html)
TW (1) TW200911767A (cg-RX-API-DMAC7.html)
WO (2) WO2009021749A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1986633T3 (pl) * 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
MX2018012018A (es) 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
EP3641741B1 (en) 2017-06-19 2024-03-20 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (cg-RX-API-DMAC7.html) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
DE59206989D1 (de) * 1991-08-08 1996-10-02 Ciba Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
ES2157268T5 (es) * 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
JP3928070B2 (ja) * 1994-06-30 2007-06-13 スリーエム カンパニー 硬化指示性成形及びコーティング組成物
CA2191238C (en) * 1994-06-30 2004-01-27 Joel D. Oxman Dental impression material with cure-indicating dye
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
WO2000068210A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenone und ihre verwendung als herbizide
WO2000068228A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft 4-(3',4'-heterocyclylbenzoyl) pyrazole als herbizide
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
US6770644B1 (en) * 1999-09-24 2004-08-03 Ono Pharmaceuticals Co., Ltd. Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
WO2002044189A1 (fr) * 2000-11-30 2002-06-06 Canon Kabushiki Kaisha Element luminescent et afficheur
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
AU2004247627A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
JP4895811B2 (ja) * 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
WO2005029187A1 (en) * 2003-09-22 2005-03-31 Agfa-Gevaert Photopolymerizable composition.
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2005074375A2 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
KR100718765B1 (ko) * 2004-08-19 2007-05-15 주식회사 엘지화학 버퍼층을 포함하는 유기 발광 소자 및 이의 제작 방법
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ZA200707896B (en) * 2005-03-14 2009-07-29 High Point Pharma Llc Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
KR101408026B1 (ko) * 2005-12-02 2014-06-20 사켐,인코포레이티드 음이온-교환 치환 크로마토그래피 공정 및 음이온-교환치환 크로마토그래피 공정에서 디스플레이서 화합물들로서사용하기 위한 음이온성 유기 화합물들
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
PL1986633T3 (pl) * 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
WO2009021748A2 (en) 2009-02-19
BRPI0811548A2 (pt) 2014-11-18
MX2009011967A (es) 2009-11-19
CA2685590A1 (en) 2009-02-19
AR068810A1 (es) 2009-12-09
CL2008002391A1 (es) 2009-05-22
WO2009021749A2 (en) 2009-02-19
US20100267961A1 (en) 2010-10-21
JP2010535830A (ja) 2010-11-25
CN101896475A (zh) 2010-11-24
US20090048314A1 (en) 2009-02-19
KR20100075777A (ko) 2010-07-05
US8138351B2 (en) 2012-03-20
AU2008286324A1 (en) 2009-02-19
RU2009141831A (ru) 2011-05-20
MX2009011916A (es) 2009-11-18
JP2010535829A (ja) 2010-11-25
AU2008286325A1 (en) 2009-02-19
WO2009021749A8 (en) 2009-09-11
WO2009021748A3 (en) 2009-04-02
CN101679323A (zh) 2010-03-24
EP2176246A2 (en) 2010-04-21
BRPI0811315A2 (pt) 2015-01-27
IL201908A0 (en) 2010-06-16
CA2685939A1 (en) 2009-02-19
TW200911767A (en) 2009-03-16
PE20090604A1 (es) 2009-05-16
EP2188270A2 (en) 2010-05-26
WO2009021749A3 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of Duchenne muscular dystrophy
ZA200806630B (en) Method of treatment for muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
SI2170396T1 (sl) Kombinacije zdravil za zdravljenje duchennove mišične distrofije
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
EP2350641A4 (en) Methods of Treatment
ZA200806986B (en) Treatment of duchenne muscular dystrophy
GB0715937D0 (en) Method of treatment og duchenne muscular dystrophy
GB0817067D0 (en) Intestinal treatment
PT2318573T (pt) Método de tratamento anticorrosão
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0614690D0 (en) Method of treatment of duchenne muscular dystrophy
GB0602767D0 (en) Treatment of muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0619283D0 (en) Treatment of duchenne muscular dystrophy
GB0623985D0 (en) Treatment of duchenne muscular dystrophy
GB0617739D0 (en) Treatment of duchenne muscular dystrophy
GB0623983D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)